NextPlat (NASDAQ:NXPL) Stock Rating Upgraded by Litchfield Hills Research

NextPlat (NASDAQ:NXPL) was upgraded by equities researchers at Litchfield Hills Research to a “strong-buy” rating in a note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings upgraded shares of NextPlat from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. One research analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.00.

NextPlat Stock Up 2.0%

NXPL stock opened at $6.48 on Wednesday. The stock has a fifty day moving average of $6.35 and a 200-day moving average of $5.93. NextPlat has a fifty-two week low of $3.38 and a fifty-two week high of $11.10. The company has a market capitalization of $17.56 million, a price-to-earnings ratio of -1.50 and a beta of 1.90. The company has a debt-to-equity ratio of 0.05, a quick ratio of 2.12 and a current ratio of 2.56.

NextPlat (NASDAQ:NXPL) last announced its quarterly earnings data on Thursday, May 14th. The company reported ($0.42) earnings per share (EPS) for the quarter. The firm had revenue of $9.86 million during the quarter. NextPlat had a negative net margin of 23.14% and a negative return on equity of 58.05%.

Institutional Investors Weigh In On NextPlat

An institutional investor recently bought a new stake in NextPlat stock. Citadel Advisors LLC bought a new position in shares of NextPlat Corp. (NASDAQ:NXPL) in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 48,176 shares of the company’s stock, valued at approximately $40,000. Citadel Advisors LLC owned approximately 0.19% of NextPlat as of its most recent SEC filing. Institutional investors own 1.30% of the company’s stock.

NextPlat Company Profile

NextPlat Corp operates as a healthcare and e-commerce company in Europe, North America, South America, the Asia and Pacific, and Africa. The company operates full-service retail specialty services pharmacies that provides prescription pharmaceuticals prescription pharmaceuticals, third-party administration, risk and data management services, compounded medications, tele-pharmacy services, anti-retroviral medications, medication therapy management, contracted pharmacy services, and health practice risk management to healthcare organizations and providers, as well as supplies prescription medications to long-term care facilities.